Czech National Bank Acquires 35,153 Shares of Johnson & Johnson $JNJ

Key Points

• The Czech National Bank increased its stake in Johnson & Johnson by 6.4%, acquiring 35,153 shares for a total of 588,129 shares overall, valued at approximately $89.8 million.
• Johnson & Johnson reported earnings of $2.77 per share for the last quarter, surpassing estimates, with revenue reaching $23.74 billion, an increase of 5.8% year-over-year.
• The company recently announced a quarterly dividend of $1.30, reflecting a dividend yield of 2.9%, with a payout ratio of 55.61%.

Czech National Bank boosted its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 6.4% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 588,129 shares of the company's stock after buying an additional 35,153 shares during the quarter. Johnson & Johnson makes up about 0.7% of Czech National Bank's investment portfolio, making the stock its 20th largest holding. Czech National Bank's holdings in Johnson & Johnson were worth $89,837,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in JNJ. Nuveen LLC bought a new stake in Johnson & Johnson during the first quarter valued at approximately $1,369,188,000. GAMMA Investing LLC grew its position in Johnson & Johnson by 24,450.4% during the first quarter. GAMMA Investing LLC now owns 7,215,367 shares of the company's stock valued at $1,196,596,000 after buying an additional 7,185,977 shares during the period. Bank of New York Mellon Corp grew its position in Johnson & Johnson by 26.4% during the first quarter. Bank of New York Mellon Corp now owns 23,182,464 shares of the company's stock valued at $3,844,580,000 after buying an additional 4,842,582 shares during the period. Pacer Advisors Inc. grew its position in Johnson & Johnson by 1,382.0% during the first quarter. Pacer Advisors Inc. now owns 3,030,084 shares of the company's stock valued at $502,509,000 after buying an additional 2,825,626 shares during the period. Finally, Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in Johnson & Johnson during the fourth quarter valued at approximately $349,206,000. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Trading Down 0.3%

Shares of JNJ opened at $177.49 on Tuesday. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $181.16. The company has a market cap of $427.46 billion, a P/E ratio of 18.98, a P/E/G ratio of 2.27 and a beta of 0.40. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. The company's fifty day simple moving average is $171.25 and its 200-day simple moving average is $161.36.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, beating the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The business had revenue of $23.74 billion for the quarter, compared to the consensus estimate of $22.85 billion. During the same quarter in the prior year, the firm posted $2.82 earnings per share. The business's revenue for the quarter was up 5.8% on a year-over-year basis. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th were paid a $1.30 dividend. The ex-dividend date of this dividend was Tuesday, August 26th. This represents a $5.20 annualized dividend and a dividend yield of 2.9%. Johnson & Johnson's dividend payout ratio is currently 55.61%.

Analyst Ratings Changes

A number of equities analysts have weighed in on JNJ shares. Wall Street Zen upgraded shares of Johnson & Johnson from a "hold" rating to a "buy" rating in a research report on Saturday. Morgan Stanley upped their price target on shares of Johnson & Johnson from $171.00 to $176.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 17th. Piper Sandler reiterated an "overweight" rating on shares of Johnson & Johnson in a research report on Thursday, July 17th. UBS Group upped their price target on shares of Johnson & Johnson from $180.00 to $190.00 and gave the stock a "buy" rating in a research report on Thursday, July 17th. Finally, Royal Bank Of Canada boosted their target price on shares of Johnson & Johnson from $181.00 to $185.00 and gave the stock an "outperform" rating in a report on Thursday, July 17th. Two analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat, Johnson & Johnson has an average rating of "Moderate Buy" and an average price target of $176.29.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the sale, the executive vice president owned 178,013 shares of the company's stock, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 0.16% of the company's stock.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.